Atomic AI vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Atomic AI is a San Francisco biotech using AI and structural biology to design RNA-targeting therapeutics; founded in 2021 by Raphael Townshend (AlphaFold co-contributor); raised $35M Series A in 2022;
About
Atomic AI is a biotechnology company founded in 2021 and headquartered in San Francisco, California, at the intersection of artificial intelligence and RNA biology. The company was co-founded by Raphael Townshend, a key contributor to machine learning methods for molecular structure prediction including work related to AlphaFold, reflecting the founding team's deep expertise in applying AI to three-dimensional molecular structure. Atomic AI's platform combines machine learning with structural biology to understand and predict RNA structure and RNA-protein interactions — a capability central to designing drugs that target RNA molecules rather than proteins.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.